Mavrakanas TA, et al. - Via this meta-analysis of five randomized trials with 1,902 patients with CKD, researchers investigated if shorter dual antiplatelet therapy (DAPT) vs longer DAPT in patients with drug-eluting stents and CKD is related to lower mortality or major adverse cardiovascular event rates. They included randomized trials comparing different DAPT duration strategies in patients with drug-eluting stents; these studies were identified via Medline literature research. A composite of all-cause mortality, myocardial infarction, stroke, or stent thrombosis (definite or probable) was considered as the primary outcome; the secondary outcome was major bleeding. Findings were suggestive of non-inferiority of short DAPT vs longer DAPT in patients with CKD and drug-eluting stents. Concerning stent thrombosis, no definite conclusions could be drawn due to imprecision in estimates (few events and wide confidence intervals).